ATLAS-2
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
- Stage
- klaar
- Medicine
- rivaroxaban
- Population
- ASCVD
- Phase
- III
- First Patient In
- 15 May 2009
- Last Patient In
- 1 June 2011
- Last Patient Last Visit
- -
Board Contact
